Related references
Note: Only part of the references are listed.Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients
J. Rogado et al.
EUROPEAN JOURNAL OF CANCER (2019)
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study
Thomas S. Uldrick et al.
JAMA ONCOLOGY (2019)
Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma
Young Kwang Chae et al.
SCIENTIFIC REPORTS (2019)
PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma
Vinod Varki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Head and Neck Cancers-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
William M. Lydiatt et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients
Olivier Dereure et al.
DERMATOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death A Systematic Review and Meta-analysis
Agnieszka K. Thompson et al.
JAMA DERMATOLOGY (2016)
Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas
M. Reigneau et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012
Howard W. Rogers et al.
JAMA DERMATOLOGY (2015)
Comparative Immune Phenotypic Analysis of Cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in Immune-Competent Individuals: Proportional Representation of CD8+ T-Cells but Not FoxP3+ Regulatory T-Cells Is Associated with Disease Stage
Andrew Freeman et al.
PLOS ONE (2014)
Staging for Cutaneous Squamous Cell Carcinoma as a Predictor of Sentinel Lymph Node Biopsy Results Meta-analysis of American Joint Committee on Cancer Criteria and a Proposed Alternative System
Adam R. Schmitt et al.
JAMA DERMATOLOGY (2014)
Evaluation of AJCC Tumor Staging for Cutaneous Squamous Cell Carcinoma and a Proposed Alternative Tumor Staging System
Anokhi Jambusaria-Pahlajani et al.
JAMA DERMATOLOGY (2013)
Factors Predictive of Recurrence and Death From Cutaneous Squamous Cell Carcinoma A 10-Year, Single-Institution Cohort Study
Chrysalyne D. Schmults et al.
JAMA DERMATOLOGY (2013)
A systematic review of worldwide incidence of nonmelanoma skin cancer
A. Lomas et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Comparison and evaluation of the current staging of cutaneous carcinomas
Helmut Breuninger et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2012)
A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics
Sharifeh Farasat et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells
Rachael A. Clark et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Share Paper
